MeasuredReferenceSunitinib targets CAMK2D, MYLK4, FLT3. Strongest hallmark effect: tumor promoting inflammation.
Top hallmarks
- tumor promoting inflammation5.8k
- evading apoptosis5.0k
- proliferation4.9k
Top pathways disrupted
- pi3k akt mtor signaling11.3k
- apical junction10.8k
- allograft rejection10.2k
Resistance landscape — Sunitinib
MeasuredReference10 known oncogenic variants exist on Sunitinib's top targets — see detail for inhibition impact.